Related Experiment Video
Updated: Aug 26, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Available Alternative Biologics and Disease Groups Influence Biologic Drug Survival in Patients with Psoriasis and
Sohee Oh1, Sungjun Choi2, Hyun-Sun Yoon2,3
1Department of Biostatistics, SMG-SNU Boramae Medical Center, Seoul, Korea.
Background:
Factors other than efficacy and safety could influence the survival of biologics in patients with psoriasis. Little is known about whether different disease groups affect drug survival of biologics or not.
Objective:
This study aimed to investigate whether the availability of alternative biologics and disease groups could influence drug survival of biologics approved for psoriasis and psoriasis arthritis (PsA).
Methods:
A nationwide population-based retrospective cohort study was conducted using the Health Insurance and Review Assessment data in Korea between January 2009 and August 2019.
Results:
The drug survival analysis included 5,634 biologic episodes. Ustekinumab was the most frequently prescribed drug (n=2,488, 44.2%). Multivariable time-dependent Cox regression analysis showed that higher age, female sex, no comorbidity, concomitant cyclosporine or acitretin use, biologic-experienced and use of tumor necrosis factor (TNF)-α inhibitors were predictors of drug discontinuation. PsA was a predictor of drug persistence, particularly for TNF-α inhibitors. Ustekinumab and adalimumab discontinuation significantly increased after introducing secukinumab and ustekinumab, respectively.
Conclusion:
The availability of alternative biologics and disease groups affect biologic drug survival in patients with psoriasis and PsA.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Bioequivalence: Overview
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Comparing the Survival Analysis of Two or More Groups

